IP Library › Granted Patent US 7,384,632
Granted Patent B2
US 7,384,632 · App. 10/312,316 · Granted Jun 10, 2008

Agonist anti-trk-C monoclonal antibodies

Assignee: Genentech, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,384,632
App. No.
10/312,316
Granted
Jun 10, 2008
Kind
B2
Abstract

The invention concerns agonist anti-trkC monoclonal antoibodies which mimic certain biological activities of NT-3, the native ligand of trkC. The invention further concerns the use of such antibodies in the prevention and/or treatment of cellular degeneration, including nerve cell damage associated with acute nervous cell system injury and chronic neurodegenerative diseases, including peripheral neuropathy.

Claims (2)

1. A human anti-TrkC antibody selected from the group consisting of antibodies 6.1.2 (ATCC No. PTA-2148), 6.4.1 (ATCC No. PTA-2150), 2345 (ATCC No. PTA-2146), 2349 (ATCC No. PTA-2153), 2.5.1 (ATCC No. PTA-2151), and 2344 (ATCC No. PTA-2144).

2. The antibody of claim 1 selected from the group consisting of antibodies 6.1.2 (ATCC No. PTA-2148), 6.4.1 (ATCC No. PTA-2150), 2345 (ATCC No. PTA-2146), and 2349 (ATCC No. PTA-2153).

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 30, 2003
From: DEVAUX, BRIGETTE; HONGO, JO-ANNE; PRESTA, LEONARD G.; SHELTON, DAVID L.
To: GENENTECH, INC.
Reel/Frame 014092/0429 →
Continuity (3)
Provisional Application 6023831900 · Oct 5, 2000
Provisional Application 6021314100 · Jun 22, 2000
Related Publication 20040137513A1 · Jul 15, 2004